Overview

Darzalex Faspro is approved by the U.S. Food and Drug Administration (FDA) for the treatment of newly diagnosed light chain (AL) amyloidosis in adults. This approval is under the FDA’s accelerated approval…

Overview
Vyndamax is approved by the U.S. Food and Drug Administration (FDA) for the treatment of cardiomyopathy (heart muscle disease) caused by wild-type or hereditary transthyretin-mediated amyloidosis. This treatment…

Overview
Attruby is approved by the U.S. Food and Drug Administration (FDA) for the treatment of cardiomyopathy (disorder of the heart muscle) caused by wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in…

Overview
Wainua is approved by the U.S. Food and Drug Administration (FDA) for the treatment of polyneuropathy (nerve damage) caused by hereditary transthyretin-mediated amyloidosis in adults. This medication is…

Overview
Amvuttra is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with hereditary transthyretin-mediated (hATTR) amyloidosis who have polyneuropathy (nerve damage). Amvuttra…

The Vyndaqel brand name has been discontinued in the U.S. Other brand name or generic alternatives may be available.

Overview

Vyndaqel is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to…

Overview
Onpattro is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with nerve damage resulting from hereditary transthyretin-mediated (hATTR) amyloidosis. Onpattro is also…